1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2 Aripiprazole Waena Ma'ema'e >99.0% (HPLC)
Hāʻawi ka mea hana i nā mea waena o Aripiprazole me ka maʻemaʻe kiʻekiʻe
Aripiprazole API CAS 129722-12-9
1-(2,3-Dichlorophenyl)piperazine Hydrochloride CAS 119532-26-2
7-Hydroxy-3,4-Dihydro-2(1H)-Quinolinone CAS 22246-18-0
7-(4-Bromobutoxy)-3,4-Dihydro-2(1H)-Quinolinone CAS 129722-34-5
Inoa Kimia | 1-(2,3-Dichlorophenyl)piperazine Hydrochloride |
Nā huaʻōlelo like | 2,3-DCPP HCl;1-(2,3-Dichlorophenyl)piperazine HCl;Aripiprazole EP Ka haumia B;Aripiprazole pili pūhui C |
Helu CAS | 119532-26-2 |
Helu CAT | RF-PI2268 |
Kūlana Kūʻai | Ma ka waihona, ka mana hana 30 MT / mahina |
ʻĀpana Molekala | C10H12Cl2N2·HCl |
Kaumaha Molecular | 267.58 |
Lae hehee | 245.0~247.0 ℃ |
Hoʻopaʻa a me ka ʻike | Hygroscopic.Nā mahana wela |
Solubility i ka wai | Hiki i ka wai |
Brand | Kemika Ruifu |
'ikamu | Nā kikoʻī |
Ka nana aku | Pada keʻokeʻo a i ʻole keʻokeʻo |
Maʻemaʻe / Kaʻina Hanana | >99.0% (HPLC) |
Nalo ma ka maloo | <0.50% |
Koena ma ka Ignition | <0.10% |
Hoʻokahi haumia | <0.50% |
Huina paumaele | <1.00% |
Nā Metala Kaumaha (e like me Pb) | ≤20ppm |
Infrared Spectrum | Kūlike i ka hoʻolālā |
Kūlana hoʻāʻo | Kūlana ʻoihana |
Hoʻohana | Kūwaena o Aripiprazole (CAS: 129722-12-9) |
Pūʻolo: ʻOmole, ʻeke ʻeke Aluminum, 25kg / pahu pahu pahu, a i ʻole e like me ka makemake o ka mea kūʻai aku.
Kūlana mālama:Hygroscopic.E mālama ʻia mai ka wai/makū a me nā mea hoʻoheheʻe.E hoʻopaʻa paʻa i ka pahu a waiho i loko o kahi kūlana anuanu, maloʻo a me ka makani maikaʻi.E kūʻai ma lalo o ke kinoea inert
ʻO 1-(2,3-Dichlorophenyl) piperazine Hydrochloride (CAS: 119532-26-2) kahi mea koʻikoʻi waena o Aripiprazole (CAS: 129722-12-9).ʻO Aripiprazole kahi ʻano hou o ka lipid soluble quinoline derivatives, ʻo kona ʻano hopena pharmacological ʻaʻole ia wale nō ka postsynaptic dopamine D 2 receptor antagonist, akā ʻo ka presynaptic dopamine D 2 receptor agonist, hiki iā ia ke hoʻoulu D 1, D 3, D 4 mea loaa ;loaʻa iā ia ka hopena ʻelua o ka hoʻāla ʻana a i ʻole ka mea hoʻokipa antagonistic ma 5-HT 1A receptor;loaʻa iā ia kahi hana antagonistic loa ma ka 5-HT 2A receptor.ʻOkoʻa kēia hiʻohiʻona mai ka hanauna mua, a me nā antipsychotics atypical e pili ana i ka lua o ka hanauna antipsychotic lāʻau, a no laila ua kapa ʻia ʻo dopamine system stabilizer a i ʻole ke kolu o ka hanauna antipsychotic.No ke kūʻai ʻia ʻana ma ka mākeke, hoʻohana nui ʻia i ka schizophrenia clinical, ka mālama ʻana i nā maʻi affective a me nā maʻi psychiatric ʻē aʻe.E like me ka palapala, aripiprazole loaʻa nā hopena koʻikoʻi i ka schizophrenia maikaʻi a me nā hōʻailona maikaʻi ʻole a me ka hopohopo, ke kaumaha, ka hana cognitive, ʻoiai ʻoi aku ka palekana.Ua hōʻike pū ʻia e hiki i ka lāʻau lapaʻau ke mālama i nā maʻi noʻonoʻo ʻē aʻe, e like me nā maʻi manic episodes, senile dementia e pili ana i nā maʻi noʻonoʻo, nā maʻi hopohopo, nā maʻi ʻano o nā keiki, ke kaumaha.I kēia mau lā, hoʻolaha ʻo Bristol-Myers Squibb a me Otsuka Pharmaceutical Company ua ʻae ka European Union iā Abilify (aripiprazole) i ka mālama ʻana i ka noi papa inoa schizophrenia.